SCHEMBL3592223

SCHEMBL3592223

[CH2]C(CCc1ccc(O)cc1)c1ccc(OC)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
SLC22A1 O15245 1/20 0.51
ADRB2 P07550 1/20 0.51
CHRM2 P08172 1/20 0.51
ADRB1 P08588 1/20 0.51
CYP3A4 P08684 1/20 0.51
CHRM1 P11229 1/20 0.51
TSHR P16473 1/20 0.51
NFKB1 P19838 1/20 0.51
SLC6A4 P31645 1/20 0.51
OPRM1 P35372 1/20 0.51
SLC6A3 Q01959 1/20 0.51
HIF1A Q16665 1/20 0.51
STAT3 P40763 1/20 0.49
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
CYP19A1 P11511 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7751022 0.79 STAT3 (0.55) ALDH1A1ADRB2CYP3A4STAT3PPARG
SCHEMBL16953953 0.75 PPARG (0.62) ALDH1A1LMNANPSR1CYP3A4TSHR
SCHEMBL9836311 0.74 PPARG (0.51) ALDH1A1LMNANPSR1PPARGPPARD
SCHEMBL10693648 0.74 ADRB2 (0.57) ALDH1A1LMNANPSR1SLC22A1ADRB2
SCHEMBL11617314 0.72 MEN1 (0.40) ALDH1A1ADRB2MEN1KMT2ACA2
SCHEMBL7465208 0.72 PPARG (0.43) LMNAPPARGPPARDPPARA
SCHEMBL16960024 0.72 PPARG (0.49) ALDH1A1LMNANPSR1PPARGPPARD
SCHEMBL13078133 0.71 STAT3 (0.52) ALDH1A1LMNANPSR1SLC22A1ADRB2
SCHEMBL22192868 0.71 LMNA (0.67) ALDH1A1LMNANPSR1SLC22A1ADRB2
SCHEMBL27817906 0.70 STAT3 (0.63) ALDH1A1CYP3A4STAT3PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858631-B2 Substituted pyrido [2,3-d] pyrimidinone compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-12-28 US disclosed
US-20060235019-A1 Substituted quinazolinone compounds CHIRON CORPORATION 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235019-A1 Substituted quinazolinone compounds MC4R, MC2R, MC5R ALDH1A1 2699/4885LMNA 3389/4885NPSR1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.